STEMREGEN
Develops natural plant-based stem cell enhancers and supplements to support the body's innate repair system.
Website: https://www.stemregen.co/
Cover Block
PUBLIC
| Field | Value |
|---|---|
| Name | STEMREGEN |
| Tagline | Develops natural plant-based stem cell enhancers and supplements to support the body's innate repair system. |
| Headquarters | Austin, Texas, United States |
| Founded | 2016 |
| Stage | Growth / Late Stage |
| Business Model | Direct-to-Consumer (DTC) |
| Industry | Healthtech / Nutraceuticals |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Lifestyle Business |
| Founding Team | Solo Founder |
Links
PUBLIC
- Website: https://www.stemregen.co/
- LinkedIn: https://www.linkedin.com/company/stemregen
- Crunchbase: https://www.crunchbase.com/organization/stemregen
Executive Summary
PUBLIC
STEMREGEN is a nine-year-old Austin nutraceutical company that sells plant-based supplements positioned to increase the number of stem cells circulating in the bloodstream, a thesis its founder Christian Drapeau has been researching for over two decades [Stemregen, retrieved 2025]. The company was incorporated in 2016 after Drapeau formulated what the company describes as the first product supporting Endogenous Stem Cell Mobilization, a proprietary blend of plant extracts marketed today under the Release, Mobilize and Sport SKUs [Stemregen History, retrieved 2025]. Its differentiation rests on a proprietary aloe extract branded StemAloe and on Drapeau's two-decade publication record rather than on a synthetic small-molecule platform [Stemregen ingredients page, retrieved 2026]. The leadership bench was reorganized in April 2024 with the appointment of Ryan Riley as Chief Executive Officer and Drapeau moving into a Chief Science Officer role, signaling a shift from founder-led operations toward a commercial growth phase [PRNewswire, April 2024] [The Org, retrieved 2026]. STEMREGEN reports it is trusted by more than 5,000 customers and was named to the 2025 Inc. 5000 list of fast-growing private companies [Stemregen, retrieved 2025] [Inc., retrieved 2026]. No external funding rounds have been publicly disclosed, and Tracxn lists the company as having raised zero institutional capital, suggesting a bootstrapped or founder-financed capital structure [Tracxn, retrieved 2025]. The next 12 to 18 months should test whether the post-2024 leadership can convert title sponsorship of high-visibility events such as the 2026 Biohacking Conference into repeatable acquisition channels and broader retail distribution [Yahoo Finance, retrieved 2026].
Data Accuracy: GREEN -- Confirmed by Stemregen primary site, PRNewswire, Inc., and Tracxn.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Growth / Late Stage |
| Business Model | Direct-to-Consumer (DTC) |
| Industry / Vertical | Healthtech / Nutraceuticals |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Lifestyle Business |
| Founding Team | Solo Founder |
| Funding | No disclosed institutional rounds [Tracxn, retrieved 2025] |
Company Overview
PUBLIC
STEMREGEN traces its origin to Christian Drapeau's research on aphanizomenon flos-aquae and other botanicals beginning in the early 2000s, work that culminated in 2016 with the launch of what the company describes as its first formulation supporting Endogenous Stem Cell Mobilization [Stemregen History, retrieved 2025]. The corporate parent has been associated with the name Kalyagen in third-party databases, with STEMREGEN serving as the consumer-facing brand and flagship product line [Crunchbase, retrieved 2025]. Headquarters are in Austin, Texas, a city that has become a cluster for the broader biohacking and longevity-supplement category [LinkedIn, retrieved 2026].
The most consequential corporate milestone since founding came in April 2024, when the company announced a leadership reorganization framed publicly around "expansion goals," including the appointment of Ryan Riley as Chief Executive Officer and the elevation of Drapeau to Chief Science Officer [PRNewswire, April 2024] [The Org, retrieved 2026]. That same year the company was recognized in Inc.'s custom-studio coverage of its science narrative, and in 2025 it appeared on the Inc. 5000 list of fastest-growing private companies in the United States [Inc., retrieved 2026]. In late 2025 the company announced its return as title sponsor of Dave Asprey's 2026 Biohacking Conference, a marketing commitment that suggests meaningful discretionary spend on category-defining events [Yahoo Finance, retrieved 2026].
Headcount estimates vary by source: Prospeo lists 16 employees across seven departments and ZoomInfo places the company in the 11 to 50 employee band [Prospeo.io, retrieved 2026] [ZoomInfo, retrieved 2026]. The convergence of those two figures suggests an organization in the high-teens to low-twenties range, which is consistent with a DTC nutraceutical operation that outsources manufacturing.
Data Accuracy: GREEN -- Confirmed by Stemregen primary site, PRNewswire, The Org, and Crunchbase.
Product and Technology
MIXED
The product line centers on oral capsule supplements positioned not as stem cell sources themselves but as botanical formulations intended to encourage the body to release more of its own stem cells from the bone marrow into circulation. The flagship product, Release, is described on the company site as combining "multiple clinically tested plant extracts that support both stem cell release and migration, addressing two critical aspects of stem cell function in a single formula backed by over 20 years of dedicated stem cell research from founder Christian Drapeau, MSc" [Stemregen Release page, retrieved 2025] [PUBLIC]. Adjacent SKUs include Mobilize, Sport, Accelerated Recovery Support and a bundled Daily Recovery Protocol, each carrying the same core claim that the formulation "supports the body's natural repair system by increasing circulating stem cells" [Stemregen products, retrieved 2025] [PUBLIC].
The most product-specific differentiator surfaced in the source set is StemAloe, described as a "unique extract of Aloe documented to support stem cell release from the bone marrow," which the company positions as proprietary to its formulations [Stemregen ingredients page, retrieved 2026] [PUBLIC]. Across the product pages, the company is careful to frame its claims under an educational disclaimer, stating that materials are "intended solely for informational and educational purposes" rather than as medical claims [Stemregen, retrieved 2025] [PUBLIC]. That posture is consistent with FDA dietary-supplement regulation under DSHEA, which permits structure/function claims but prohibits disease claims without drug approval.
The technology stack is a botanical-extract supply chain rather than a software or biologics platform: sourcing of plant inputs, standardized extraction, encapsulation, and DTC e-commerce fulfillment through a Shopify storefront (inferred from site signatures). A reseller program is published on the company website, with the condition that resellers operate behind password-protected pages or refrain from paid digital ads, a structure that suggests STEMREGEN intends to retain control of its paid-acquisition narrative [Stemregen reseller page, retrieved 2025] [PUBLIC].
Data Accuracy: YELLOW -- Product claims are sourced primarily from the company's own website; independent clinical literature on the specific finished formulations was not surfaced in the cited research.
Market Research and Opportunity
PUBLIC
The nutraceutical and longevity-supplement category sits at the intersection of two demand curves that have steepened over the past five years: consumer interest in healthspan extension, and consumer skepticism toward conventional pharmaceutical solutions for age-related decline. STEMREGEN's positioning is sharpened by the fact that clinical stem cell therapy itself, typically delivered through expensive overseas clinics, remains out of reach for most United States consumers, leaving an addressable gap for an oral product that claims to influence endogenous stem cell biology.
No named third-party TAM report for the specific "stem cell supplement" sub-category was surfaced in the cited research. As an analogous frame, the global dietary supplements category and the longevity-and-anti-aging category are both routinely cited by trade press as multi-hundred-billion-dollar opportunities, but those figures are not in the verified source set for this report and are therefore not reproduced here. What can be confirmed from the cited sources is that STEMREGEN serves over 5,000 customers and grew quickly enough to qualify for the 2025 Inc. 5000, which requires meaningful three-year revenue growth and a minimum revenue threshold [Stemregen, retrieved 2025] [Inc., retrieved 2026].
Demand drivers visible in the source set include the rise of the biohacking conference circuit, where Dave Asprey's event has become a high-density gathering of category buyers, and the proliferation of long-form podcast appearances by Drapeau across shows including Commune with Jeff Krasno, WealthyWellthy, and BoneCoach [Yahoo Finance, retrieved 2026] [Commune, retrieved 2026] [Wealthy Wellthy, retrieved 2026] [BoneCoach, retrieved 2026]. Founder-podcast distribution has emerged as one of the more durable customer-acquisition channels for science-forward DTC supplement brands, because it allows extended explanation of mechanism-of-action claims that paid social cannot accommodate within platform policy.
| Confirmed traction marker | Value | Source |
|---|---|---|
| Customers served | Over 5,000 | [Stemregen, retrieved 2025] |
| Inc. 5000 status | 2025 honoree | [Inc., retrieved 2026] |
| Headcount band | 11-50 employees | [ZoomInfo, retrieved 2026] |
| Headcount detail | 16 across 7 departments | [Prospeo.io, retrieved 2026] |
STEMREGEN's verifiable footprint is modest in absolute terms but has crossed the threshold required for Inc. 5000 inclusion, indicating a credible growth slope from a small base. The regulatory frame remains the swing variable: structure/function claims under DSHEA are permitted, but FTC scrutiny of substantiation for stem cell claims has been an active enforcement area in the broader category, which both raises the bar for marketing language and creates a moat for operators that invest in IRB-reviewed studies on their finished products.
Data Accuracy: YELLOW -- Customer counts and Inc. 5000 status are confirmed; specific TAM figures for the stem cell supplement sub-category were not surfaced in the cited research.
Competitive Landscape
MIXED
The competitive set facing STEMREGEN can be sorted into three broad groups. The first is the category of established botanical and longevity-supplement brands that own broad shelf presence and paid-media scale, including the publicly visible players in the Inc. 5000 nutraceutical cohort and the larger DTC longevity brands that have raised institutional capital. STEMREGEN does not appear to compete with these brands on price or breadth of SKU; instead it competes on the specificity of its mechanism story, anchored in Drapeau's two-decade publication record and the StemAloe ingredient [Stemregen, retrieved 2025]. The second group is clinical stem cell therapy, both domestic regenerative-medicine clinics and overseas medical-tourism providers in places like Panama and Mexico. STEMREGEN is positioned not as a substitute for those interventions but as an accessible adjunct or daily protocol, which expands rather than cannibalizes the clinical category. The third group is the biohacker-celebrity supplement stack, including products endorsed by figures in the Dave Asprey, Andrew Huberman and Peter Attia orbits; STEMREGEN's title sponsorship of the 2026 Biohacking Conference suggests a deliberate choice to embed inside that ecosystem rather than try to displace it [Yahoo Finance, retrieved 2026].
Where STEMREGEN has a defensible edge today, the evidence points to two assets. The first is founder credibility: Drapeau is one of a small number of supplement-industry principals with a sustained academic-style publication history on a single mechanism, and that asset compounds with each long-form podcast he appears on [Feedspot, retrieved 2026]. The second is ingredient specificity: the StemAloe trademark and the Release formulation create a product story that is harder to clone than a generic adaptogen blend [Stemregen ingredients page, retrieved 2026]. Both edges are real but perishable.
Where STEMREGEN is most exposed is on capital and channel. With no disclosed institutional funding, the company likely cannot match the paid-acquisition spend of venture-backed longevity brands, and the reseller policy that restricts paid digital ads further narrows the channel mix [Tracxn, retrieved 2025] [Stemregen reseller page, retrieved 2025]. The most plausible 18-month scenario is bifurcated: STEMREGEN wins if the 2026 Biohacking Conference sponsorship and continued podcast distribution convert into a recurring subscription base that funds further clinical substantiation; it loses ground if a venture-backed entrant launches a competing endogenous-mobilization product with comparable ingredient claims and ten times the paid-media budget.
Data Accuracy: ORANGE -- Competitive map is inferred from category context; no specific named competitors were surfaced in the cited research.
Opportunity
PUBLIC
The upside case for STEMREGEN is that it becomes the default science-forward brand inside the endogenous stem cell mobilization sub-category, a position that is currently uncontested by name in the cited research.
The headline opportunity
The single largest plausible outcome is that STEMREGEN converts Drapeau's two-decade research narrative and the StemAloe ingredient into a category-defining brand the way a small number of single-ingredient stories (urolithin A, NMN, spermidine) have defined adjacent longevity sub-categories over the past five years. The cited evidence makes that outcome reachable rather than aspirational on three counts: a verifiable customer base of more than 5,000, Inc. 5000 inclusion in 2025 indicating a credible growth rate from that base, and a 2024 leadership reset that paired a new CEO with the founder in a CSO role, the standard configuration for a science-led brand preparing for a commercial scale-up [Stemregen, retrieved 2025] [Inc., retrieved 2026] [PRNewswire, April 2024].
Growth scenarios
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Biohacker channel lock-in | STEMREGEN becomes the default stem cell SKU inside the Asprey-adjacent biohacking ecosystem | Title sponsorship of the 2026 Biohacking Conference converts to multi-year exclusivity and influencer protocols | Title sponsor status is already confirmed [Yahoo Finance, retrieved 2026] |
| Clinic and practitioner channel | The product is adopted as a daily protocol by regenerative medicine and longevity clinics as an adjunct to in-clinic procedures | Practitioner reseller program scales beyond the current password-protected model | Reseller infrastructure already exists [Stemregen reseller page, retrieved 2025] |
| International expansion | Distribution in markets where supplement claims regulation is more permissive accelerates ahead of the United States footprint | Existing Turkey LinkedIn presence expands into formal distributor agreements | Stemregen Turkiye entity is publicly listed [LinkedIn, retrieved 2026] |
What compounding looks like
The flywheel for a brand of this profile turns on three reinforcing loops. The first is content compounding: each Drapeau podcast appearance creates an evergreen asset that drives organic traffic for years, and the existing catalog of appearances on Commune, WealthyWellthy, BoneCoach and others suggests that loop is already in motion [Feedspot, retrieved 2026] [Commune, retrieved 2026]. The second is subscription economics: a daily-use supplement converts a one-time buyer into a recurring revenue stream, and the company's Daily Recovery Protocol bundle is structured to encourage exactly that behavior [Stemregen, retrieved 2025]. The third is research compounding: each additional study Drapeau publishes on the underlying mechanism strengthens both the marketing claim and the regulatory defensibility, which lowers the cost of every subsequent customer acquisition.
The size of the win
Public comparables in the longevity-supplement category have demonstrated that a single-mechanism brand with credible science can build a nine-figure revenue line within a decade of launch; specific revenue figures for STEMREGEN are not in the cited source set, so the comparison is offered as scenario rather than forecast. If STEMREGEN executes on the biohacker channel lock-in scenario and reaches the revenue thresholds typical of an Inc. 5000 graduate that continues to compound, the brand could plausibly attract acquisition interest from a strategic nutraceutical platform or a longevity-focused private equity roll-up (scenario, not a forecast). The constraint on that outcome is the absence of disclosed institutional capital, which makes the company more dependent on operating cash flow than venture-backed peers and therefore more sensitive to any slowdown in DTC conversion [Tracxn, retrieved 2025].
Data Accuracy: YELLOW -- Scenarios are anchored to confirmed milestones (Inc. 5000, Biohacking Conference sponsorship, leadership reset); revenue and valuation comparisons are scenario framings rather than forecasts.
Sources
PUBLIC
[Stemregen, retrieved 2025] STEMREGEN Natural Advanced Stem Cell Support | https://www.stemregen.co/
[Stemregen, retrieved 2025] Release - Best Stem Cell Supplements for Healthy Aging | https://www.stemregen.co/products/release
[Stemregen, retrieved 2025] About | https://www.stemregen.co/pages/about
[Stemregen History, retrieved 2025] History | https://www.stemregen.co/pages/history
[Stemregen, retrieved 2025] Shop All | https://www.stemregen.co/collections/all
[Stemregen, retrieved 2025] Mobilize product page | https://www.stemregen.co/products/mobilize
[Stemregen, retrieved 2025] Daily Recovery Protocol | https://www.stemregen.co/products/daily-recovery-protocol
[Stemregen, retrieved 2025] Reseller program | https://www.stemregen.co/pages/reseller
[Stemregen ingredients page, retrieved 2026] StemAloe ingredient documentation | https://www.stemregen.co/
[Crunchbase, retrieved 2025] STEMREGEN Crunchbase profile | https://www.crunchbase.com/organization/stemregen
[LinkedIn, retrieved 2026] Stemregen company page | https://www.linkedin.com/company/stemregen
[LinkedIn, retrieved 2026] Stemregen Turkiye | https://tr.linkedin.com/company/stemregen-turkiye
[Inc., retrieved 2026] A Scientific Discovery That Unlocks Your Body's Healing Power | https://www.inc.com/inc-custom-studio/a-scientific-discovery-that-unlocks-your-bodys-healing-power/90984149
[Tracxn, retrieved 2025] Stemregen 2025 Company Profile, Team & Competitors | https://tracxn.com/d/companies/stemregen/__voAfsDeXKoF9ivgj9IaBymrd-dgFIYyTg53qQxOxZ4Y
[PRNewswire, April 2024] Nutraceutical Innovator STEMREGEN Bolsters Leadership Team | https://www.prnewswire.com/news-releases/nutraceutical-innovator-stemregen-bolsters-leadership-team-with-industry-insiders-focused-on-expansion-goals-302126881.html
[Yahoo Finance, retrieved 2026] STEMREGEN Announces Return As Title Sponsor of 2026 Biohacking Conference | https://finance.yahoo.com/news/stemregen-announces-return-title-sponsor-130000158.html
[Feedspot, retrieved 2026] 15 Best Christian Drapeau Podcast Appearances | https://podcast.feedspot.com/christian_drapeau_podcasts/
[Commune, retrieved 2026] Stem Cells, Longevity, and Healing with Christian Drapeau | https://www.onecommune.com/blog/podcast-stem-cells-longevity-and-revolutionizing-healing-with-christian-drapeau
[Wealthy Wellthy, retrieved 2026] Bridging Science and Spirituality with Christian Drapeau | https://wealthywellthy.life/podcast/296-bridging-science-spirituality-a-stem-cell-journey-w-christian-drapeau/
[BoneCoach, retrieved 2026] Stem Cells, Osteoporosis and Whole Body Health with Christian Drapeau | https://bonecoach.com/blogs/podcast/christian-drapeau-stem-cells-osteoporosis-whole-body-health
[The Org, retrieved 2026] Stemregen organizational chart | https://theorg.com/
[Prospeo.io, retrieved 2026] Stemregen employee count | https://prospeo.io/
[ZoomInfo, retrieved 2026] Stemregen company overview | https://www.zoominfo.com/
Articles about STEMREGEN
- STEMREGEN Is Selling Aging Adults a Plant Pill That Promises More Stem Cells in Circulation — Christian Drapeau's Austin nutraceutical company has 5,000-plus customers and a 2025 Inc. 5000 nod, but its repair claims sit outside the FDA drug pathway.